IN RESPONSE:
The Centre for Evidence-Based Medicine Outcome Monitoring Project (1) recently commented on Gepner and colleagues' article (2) and mentioned MacPherson and associates' trial (3) on their Web site. This watchdog group aims to monitor the reporting of prespecified outcomes in all clinical trials published in 5 top-tier medical journals, including Annals. Because these comments express concerns about "switched" or incompletely reported outcomes, we would like to describe our editorial process and potential reasons for the discrepancies noted by COMPare. We attempted to post a public comment on the group's Web site to express our concerns about their assessments, but there were no means for doing so.
We share COMPare's overarching goals to ensure the validity and reporting quality of biomedical studies, but we differ on how best to achieve those aims. We routinely ask authors of clinical trials to submit their protocols with their manuscripts, and we examine trial registries for the initial and final information entered about trials. We review both items because registries include only extracted information, do not routinely monitor whether the data in the registry match the protocol, and may not be updated when the protocol changes. We therefore rely primarily on the protocol for details about prespecified primary and secondary outcomes, study interventions and procedures, and statistical analysis. To be consistent with CONSORT recommendations, we ask authors to describe, either in the manuscript or in an appendix, any major differences between the trial registry and protocol, including changes to trial end points or procedures.
According to COMPare's protocol (4), abstractors are to look first for a protocol that has been published before a trial's start date. If they find no such publication, they are supposed to review the initial trial registry data. Thus, COMPare's review excludes most protocols published after the start of a trial and unpublished protocols or their amendments and ignores amendments or updates to the registry after a trial's start date. The initial trial registry data, which often include outdated, vague, or erroneous entries, serve as COMPare's "gold standard."
Our review indicates problems with COMPare's methods. For 1 trial (5), the group apparently considered the protocol (6) published well after data collection ended. However, they did not consider the protocol (7) published 2 years before MacPherson and associates' primary trial was published (3). That protocol (7) was more specific in describing the timing of the primary outcome (assessment of neck pain at 12 months) than the registry (assessment of neck pain at 3, 6, and 12 months), yet COMPare deemed the authors' presentation of the 12-month assessment as primary in the published trial to be "incorrect." Similarly, the group's assessment of Gepner and colleagues' trial (2) included an erroneous assumption about one of the prespecified primary outcomes, glycemic control, which the authors had operationalized differently from the abstractors. Furthermore, the protocol for that trial clearly listed the secondary outcomes that the group deemed as being not prespecified.
On the basis of our long experience reviewing research articles, we have learned that prespecified outcomes or analytic methods can be suboptimal or wrong. Regardless of prespecification, we sometimes require the published article to improve on the prespecified methods or not emphasize an end point that misrepresents the health effect of an intervention. Although prespecification is important in science, it is not an altar at which to worship. Prespecification can be misused to sanctify both inappropriate end points, such as biomarkers, when actual health outcomes are available and methods that are demonstrably inferior.
The Centre for Evidence-Based Medicine Outcome Monitoring Project's assessments seem to be based on the premise that trials are or can be perfectly designed at the outset, the initial trial registry fully represents the critical aspects of trial conduct, all primary and secondary end points are reported in a single trial publication, and any changes that investigators make to a trial protocol or analytic procedures after the trial start date indicate bad science. In reality, many trial protocols or reports are changed for justifiable reasons: institutional review board recommendations, advances in statistical methods, low event or accrual rates, problems with data collection, and changes requested during peer review. The Centre for Evidence-Based Medicine Outcome Monitoring Project's rigid evaluations and the labeling of any discrepancies as possible evidence of research misconduct may have the undesired effect of undermining the work of responsible investigators, peer reviewers, and journal editors to improve both the conduct and reporting of science.
We have led or participated in many efforts to improve the transparency and accuracy of scientific reporting. We will continue to encourage authors of clinical trials to make their protocols available to others and to update their trial registry information. We respect COMPare's effort to draw attention to the importance of accurate and complete public description of clinical trial procedures, but we do not believe that their approach-that purports to draw a simple methodological line between "good" and "bad" reporting (or editing)-serves our common cause. Until COMPare's methods are modified to provide a more accurate, complete, and nuanced evaluation of published trial reports, we caution readers and the research community against considering the group's assessments as an accurate reflection of the quality of the conduct or reporting of clinical trials.
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Annals of Internal Medicine endorses the CONSORT (Consolidated Standards of Reporting Trials) guidelines (3) on best practice in trial reporting. To reduce the risk for selective outcome reporting, CONSORT includes a commitment that all prespecified primary and secondary outcomes should be reported and that, where new outcomes are reported, it should be made clear that these were added at a later date, and when and why this was done should be explained.
The Centre for Evidence-Based Medicine Outcome Monitoring Project (COMPare) (4) aims to review all trials published going forward in a sample of top journals, including Annals. When outcomes have been incorrectly reported, we are writing letters to correct the record and audit the extent of this problem in the hope of reducing its prevalence. These trials have been published and are being used to inform decision making, and this comment is a brief correction on a matter of fact obtained by comparing 2 pieces of published literature. We are maintaining a Web site (www.COMPare -Trials.org) containing our letters and all our underlying data. We welcome specific feedback on any trial. 
